Markers in Colorectal Cancer and Clinical Trials Based Upon Them

摘要: Colorectal cancer was a model for the early discovery of processes carcinogenesis at molecular level, yet despite this, therapeutic advances have been slow. A gradual appreciation influence signaling through Ras/Raf/MEK pathway showed that tumors carrying mutations in this were resistant to EGFR inhibition, but it has not until recently targeting yielded efficacy. Patients with mutant BRAF are responsive combined approaches pathway. In 2015, reports also presented show effect HER2-amplified combinations and microsatellite unstable anti-PD1 immune checkpoint modifiers. Studies now initiated Europe, planned USA, allocate patients trials specific therapies based on characteristics their tumors, accelerated development treatments can be predicted.